Akero therapeutics CSO Rolph sells $616,299 in stock
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc stock price live, this page displays NASDAQ AKRO stock exchange data. View the AKRO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akero Therapeutics Inc real time stock price chart below.
What Is the Akero Therapeutics Inc Stock Price Today?
The Akero Therapeutics Inc stock price today is 50.45.
What Is the Stock Symbol for Akero Therapeutics Inc?
The stock symbol for Akero Therapeutics Inc is ""AKRO.""
What Stock Exchange Does Akero Therapeutics Inc Trade On?
Akero Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Akero Therapeutics Inc a Good Stock to Buy?
Determining whether Akero Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKRO quote. (ISIN: US00973Y1082)
What Is the Akero Therapeutics Inc Stock Price Today?
The Akero Therapeutics Inc stock price today is 50.45.
What Is the Stock Symbol for Akero Therapeutics Inc?
The stock symbol for Akero Therapeutics Inc is ""AKRO.""
What Stock Exchange Does Akero Therapeutics Inc Trade On?
Akero Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Akero Therapeutics Inc a Good Stock to Buy?
Determining whether Akero Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKRO quote. (ISIN: US00973Y1082)
50.45
0.00(0.00%)
Real-time Data·
Fair Value
An estimate of a Akero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.44
51.13
52 wk Range
21.34
58.40
AKRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
1/2
Fair Value
An estimate of a Akero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.4451.13
52 wk Range
21.3458.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AKRO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Akero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
76.27
Upside
+51.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Akero Therapeutics CEO Cheng sells $1.5m in stock
- Investing.com
- Akero therapeutics CSO Rolph sells $616,299 in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Akero Therapeutics Inc Company Profile
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Compare AKRO to Peers and Sector
Metrics to compare | AKRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKROPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.9x | −3.3x | −0.5x | |
PEG Ratio | 0.92 | −0.01 | 0.00 | |
Price/Book | 3.7x | 2.0x | 2.6x | |
Price / LTM Sales | - | 9.7x | 3.3x | |
Upside (Analyst Target) | 48.7% | 200.6% | 43.4% | |
Fair Value Upside | Unlock | 6.1% | 7.1% | Unlock |
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 76.27
(+51.18% Upside)
Earnings
Latest Release
Aug 08, 2025
EPS / Forecast
-0.86 / -0.90
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Akero Therapeutics Trade On?
Akero Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Akero Therapeutics?
The stock symbol for Akero Therapeutics is "AKRO."
What Is the Akero Therapeutics Market Cap?
As of today, Akero Therapeutics market cap is 4.02B.
What Is Akero Therapeutics's Earnings Per Share (TTM)?
The Akero Therapeutics EPS (TTM) is -3.74.
When Is the Next Akero Therapeutics Earnings Date?
Akero Therapeutics will release its next earnings report on 07 Aug 2025.
From a Technical Analysis Perspective, Is AKRO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Akero Therapeutics Stock Split?
Akero Therapeutics has split 0 times.
How Many Employees Does Akero Therapeutics Have?
Akero Therapeutics has 69 employees.
What is the current trading status of Akero Therapeutics (AKRO)?
As of 08 Aug 2025, Akero Therapeutics (AKRO) is trading at a price of 50.45, with a previous close of 50.45. The stock has fluctuated within a day range of 49.44 to 51.13, while its 52-week range spans from 21.34 to 58.40.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.